arrow
M

Mark B. Faries

cedars-sinai medical center
H指数:53
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma

国际调查:III期黑色素瘤新辅助全身治疗后行哨兵淋巴结手术的证据

2025-10-140
OA
Mechanisms of recurrence following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial

mRNA-4157(V940)联合pembrolizumab或pembrolizumab单药治疗在切除的黑素瘤中复发的机制:来自mRNA-4157-P201(KEYNOTE-942)试验

2024-09-010
PRE
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

个体化新抗原治疗mRNA-4157 (V940) 联合pembrolizumab与pembrolizumab单药治疗黑色素瘤 (KEYNOTE-942): 一项随机2b期研究

LANCET
IF88.5
2024-02-01121
PRE
mRNA-4157 (V940) individualized neoantigen therapy plus pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response

mRNA-4157 (V940) 个体化新抗原治疗联合帕博利珠单抗与帕博利珠单抗治疗高危黑色素瘤: 临床疗效和反应相关性

2023-10-011
OA
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis
2023-08-034
OAAI
Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma
2023-05-060
OA
Sentinel lymph node biopsy in patients with T1a cutaneous malignant melanoma: A multicenter cohort study
2023-01-0113
PRE